Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-α in interferon nonresponders with chronic hepatitis C0

Journal of Viral Hepatitis

Volumn 6, Issue SUPPL. 1, 1999, Pages 53-58

  Ferenci, P ^a,e   Stauber, R ^b   Steindl Munda, P ^a   Gschwantler, M ^c   Fickert, P ^b   Datz, C ^c   Muller C ^a   Hackl, F ^d   Rainer, W ^c   Watkins Riedel, T ^a   Lin, W ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c Rudolfsspital ^*  (Austria)

^d ELISABETHINEN HOSPITAL   (Austria)

^e Gastroenterology and Hepatology   (Austria)

Author keywords

Chronic hepatitis C; Interferon ; Ribavirin; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEMOGLOBIN DETERMINATION; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; ALANINE TRANSAMINASE; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL;

EID: 0032805188     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1999.00005.x     Document Type: Article

References (30)

1. Poynard T, Bedossa P, Chevallier M et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group N Engl J Med 1995; 332: 1457-1462.
2. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C. effects of dose increment and duration of treatment on response rates. Results of the first multicenter Australian trial. J Hepatol 1995; 23: 487-496.
3. Reichard O, Foberg U, Fryden A et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks. Hepatol 1994; 19: 280-285.
4. Kasahara A, Hayashi N, Hiramatsu N et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C. a multicenter randomized controlled trial. Hepatol 1995; 21: 291-297.
5. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Ther Group N Engl J Med 1989; 321: 1501-1506.
6. Marcellin P, Boyer N, Giostra E et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatol 1991; 13: 393-397.
7. Chemello L, Bonetti P, Cavaletto L et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatol 1995; 22: 700-706.
8. Bellary S, Smith DG, Bankes P et al. High dose interferon alpha-2b therapy for chronic hepatitis C. an open label study of the response and predictors of response. Am J Gastroenterol 1995; 90: 259-262.
9. Caporaso N, Suozzo R, Morisco F et al. Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year. Ital J Gastroenterol 1993; 25: 482-486.
10. Picciotto A, Callea F, Varagona G et al. Lymphoblastoid interferon therapy in chronic hepatitis C. Biochemical, virological and histological evaluation of two different doses. Liver 1995; 15: 20-24.
11. Fong TL, Morgan TR, Phan CG, Hoefs JC. Raising the dose of interferon does not improve the response in chronic hepatitis C. J Clin Gastroenterol 1995; 20: 42-44.
12. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study. Dig Dis Sci 1993; 38: 612-618.
13. Marcellin P, Pouteau M, Martinot Peignoux M et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterol 1995; 109: 156-165.
14. Ferenci P, Stauber R, Propst A et al. Dose increase augments the response rate to interferon alpha in chronic hepatitis C. Dig Dis Sci 1996; 41: 109S-114S.
15. Takano S, Ito Y, Yokosuka O et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatol 1994; 20: 558-564.
16. Beloqui O, Prieto J, Suarez M et al. N-acetyl cysteine enhances the response to interferon-α in chronic hepatitis C. A pilot study. J Interferon Res 1993; 13: 279-282.
17. Reichard O, Norkrans G, Fryden A et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 83-87.
18. Brillanti S, Garson J, Foli M et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterol 1994; 107: 812-817.
19. Davis GL, Esteban-Mur R, Rustgi V et al. Retreatment of relapse after interferon therapy for chronic hepatitis C. An international randomized controlled trial of interferon plus ribavirin vs. interferon alone. Hepatol 1997; 26: 247A.
20. Bellobuono A, Mondazzi L, Tempini S et al. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C. a randomized clinical trial. J Viral Hepat 1997; 4: 185-191.
21. Hofmann H. Genotypes and virus load in patients with hepatitis C infection. Infection 1995; 23: 133-138.
22. Oesterreicher C, Hammer J, Koch U et al. HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis. Kidney Int 1995; 48: 1967-1971.
23. Schmidt W, Wu P, Han J et al. Distribution of hepatitis C virus (HCV) RNA in whole blood and blood cell fractions: Plasma HCV RNA analysis under-estimates circulating virus load. J Infect Dis 1997; 176: 20-26.
24. Chang T, Young K, Yang Y, Lei H, Wu H. Hepatitis C Virus RNA in peripheral blood mononuclear cells: comparing acute and chronic hepatitis C virus infection. Hepatol 1996; 23: 977-981.
25. Watkins-RiedelT, Hofmann H, Steindl P, Müller C, Ferenci P. Comparison of whole blood and serum for the detection of hepatitis C virus (HCV) RNA in interferon (IFN) treated patients. Hepatol 1997; 26: 140A.
26. Zeuzem S, Schmidt JM, von Lee JH et al. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatol 1998; 28: 245-252.
27. Lindsay KL, Davis GL, Schiff ER et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C. a randomized multicenter trial. Hepatol 1996; 24: 1034-1040.
28. Lam NP, Neumann AU, Gretch DR et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatol 1997; 26: 226-231.
29. Di Bisceglie AM, Shindo M, Fong TL et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatol 1992; 16: 649-654.
30. Lee JH, von Wagner M, Roth WK et al. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. J Hepatol 1998; 29: 29-23.